Artificial reddener: New synthetic route for EPO and other glycoprotein analogues
Monday, October 19, 2009 - 03:28
in Health & Medicine
(PhysOrg.com) -- Erythropoetin, abbreviated EPO, has gained a scandalous reputation as a doping agent for racing cyclists. The name is derived from the ancient Greek erythros "red" and poiein `to make`, a fitting designation for this important growth factor, which is responsible for the formation of red blood cells in the body. Biotechnologically produced erythropoetin, aside from its implementation as a drug for cyclists, is primarily used to treat anemia in dialysis patients after aggressive chemotherapy.
Read the whole article on Physorg
More from Physorg
Related
- Drugs to combat anemia in cancer patients increase risk of deathThu, 30 Apr 2009, 17:38:55 EDT
- New form of intravenous iron treats anemia in chronic kidney disease patients on dialysisWed, 28 Jan 2009, 14:11:40 EST
- Anemic patients with MDS gain long-term benefits from erythropoietin and a myeloid growth factorThu, 17 Sep 2009, 17:49:36 EDT
- Treatment with anti-anemia drugs may not be safe for multiple myeloma patientsMon, 4 Aug 2008, 17:43:05 EDT
- Drug does not increase suitability for dialysis of surgically-enlarged blood vesselsTue, 13 May 2008, 19:14:23 EDT